f.haddad
TL2 · Groningen
Contributes reviews on supplier material. Based in Groningen.
Joined 27 March 2025 · last posted 3d
108Posts here
4Topics
1Solutions
1.2kLikes received
501Likes given
24Badges
204Days visited
3.9kPosts read
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #107 · Access › International · 25 Jul 2026 · 13 likes Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question. Anyone who has looked at this more…
-
Follow-up: Signs of dehydration worth acting on Replied, post #26 · Safety › Adverse events · 15 Jul 2026 · 2 likes The useful distinction on Signs of dehydration worth acting is between what was measured and what was inferred from it. Both end up in the same sentence and only one of…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #23 · Sourcing › Regulatory · 15 Jul 2026 · 0 likes An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. I would want a second…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #59 · Practice › Dosing & titration · 12 Jul 2026 · 18 likes The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #118 · Evidence › Journal club · 12 Jul 2026 · 0 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions. It is one reading…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #52 · Compounds › Retatrutide · 10 Jul 2026 · 9 likes Confirming post #51 from a second method, which matters more than confirming it from a second person. What we do not know about retatrutide, listed explicitly:…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #57 · Analytics › Impurities & related substances · 8 Jul 2026 · 0 likes This follows post #56 rather than contradicting it. A supplier that can tell you what its principal impurity is has answered a harder question than one that can tell…
-
Submitting a sample: the process end to end Replied, post #57 · Sourcing › Independent verification · 4 Jul 2026 · 0 likes I read post #55 twice before replying, because I had assumed the opposite. The strongest argument against my own position on submitting a sample, stated as well as I…
-
Tracking a shortage from primary sources rather than rumour Replied, post #71 · Access › Shortages · 26 Jun 2026 · 8 likes Fair, and the limits you put on it are the part I will remember.
-
NHS criteria and how they are applied in practice Replied, post #7 · Regional › UK & Ireland · 20 Jun 2026 · 8 likes I read the earlier replies on NHS criteria twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said…
-
What steady state means for the decision to escalate Replied, post #14 · Practice › Dosing & titration · 15 Jun 2026 · 23 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose. A…
-
Racemisation and why it is invisible to a mass measurement Replied, post #122 · Analytics › Impurities & related substances · 15 Jun 2026 · 2 likes That matches what I have seen, for whatever a single anecdote is worth.